Business Context and Reporting Period
Company: Trinity Biotech plc
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2003
Business Overview: Trinity Biotech develops, manufactures, and markets diagnostic test kits for clinical laboratories and point-of-care settings. The company operates globally with manufacturing facilities in Ireland, the USA, Germany, and Sweden. Its portfolio includes over 500 products testing for infectious diseases, blood coagulation disorders, and autoimmune conditions.
Key Financial Metrics (Year Ended Dec 31, 2003)
| Metric | 2003 (US$) | 2002 (US$) |
|---|---|---|
| Revenues | 65,675,398 | 51,978,422 |
| Cost of Sales | (32,876,951) | (25,689,879) |
| Gross Profit | 32,798,447 | 26,288,543 |
| Operating Profit | 9,668,602 | 6,582,861 |
| Net Profit After Tax | 5,797,474 | 4,896,911 |
| Basic EPS | $0.13 | $0.12 |
| Diluted EPS | $0.12 | $0.12 |
| Total Assets | 118,091,489 | 89,798,458 |
| Shareholders' Equity | 80,261,927 | 62,537,284 |
| Long-term Liabilities | 17,517,713 | 7,745,442 |
| Cash and Cash Equivalents | 20,563,418 | 5,807,514 |
Note: Financial statements are prepared under Irish GAAP. US GAAP net profit for 2003 was $5,145,594.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 26% to $65.7 million, driven primarily by the full-year contribution of the Sigma Haemostasis and Sigma Clinical Chemistry product lines acquired in 2002.
- Product Segment Performance:
- Haemostasis: Revenue surged 77% to $24.4 million.
- Clinical Chemistry: Revenue increased 1,557% to $6.1 million.
- Infectious Diseases: Revenue declined 7% to $35.1 million, largely due to a $2.2 million drop in sales under the distribution agreement with Inverness Medical/Wampole.
- Operating Expenses: Administrative expenses rose 33% to $17.1 million due to expanded sales and marketing efforts in the US, Germany, and UK to support new product lines. R&D expenses increased 17% to $5.2 million.
- Profitability: Operating profit grew 47% to $9.7 million. Net profit increased 18% to $5.8 million, though this was impacted by a $1.1 million write-off of the investment in associate HiberGen Limited.
- Liquidity: Cash and cash equivalents increased significantly from $5.8 million to $20.6 million, supported by operating cash flow and the issuance of $20 million in convertible debentures.
Guidance, Outlook, Risks, and Contingencies
- Legal Proceedings (Inverness Medical): The company filed suit in December 2003 against Inverness Medical for breach of contract, alleging attempts to convert customers to competitor products. In January 2004, Inverness countersued seeking an injunction to prevent Trinity from selling directly in the US. The court denied the preliminary injunction on January 28, 2004. Trinity has increased its US direct sales force to approximately 70 staff to recapture lost sales.
- Legal Proceedings (Xtrana Inc.): Litigation regarding the 2001 Biopool acquisition was settled in June 2003 with a payment of approximately $1.5 million.
- Regulatory Milestone: The FDA approved the UniGold HIV test on December 29, 2003, allowing sales in US clinical laboratories. The company is pursuing a CLIA waiver to expand use to point-of-care settings.
- Capital Resources: The company completed a $10 million club banking facility in June 2003 and a $20 million private placement of 3% convertible debentures in July 2003. Subsequent to year-end, an additional $5 million in convertible debentures and a $22.5 million private placement of shares were completed.
- Risks:
- Currency: Significant exposure to Euro/USD fluctuations as expenses are largely Euro-denominated while revenues are primarily USD.
- Competition: Highly competitive industry with larger rivals (e.g., Roche, Abbott, Dade-Behring).
- Patents: Reliance on limited patent life and potential challenges to intellectual property.
Investor Verification Checklist
- US Sales Recovery: Verify the success of the new direct sales force in offsetting the revenue decline from the Inverness Medical distribution agreement.
- Legal Outcomes: Monitor the status of the ongoing litigation with Inverness Medical and potential financial impacts.
- Dilution Risk: Assess the impact of outstanding convertible debentures ($13.2 million remaining principal) and warrants on future earnings per share.
- Regulatory Approvals: Track the progress of the CLIA waiver for the UniGold HIV test to enable point-of-care sales.
- Currency Hedging: Review the effectiveness of the company's forward currency hedging policy in mitigating Euro expense risks.